Alzheimer Disease & Biomarkers
Evaluating blood- and CSF-based biomarkers and understanding when biomarker results agree—or disagree—with established measures of Alzheimer disease pathology.
We investigate memory and neurodegenerative disorders through clinical phenotyping, biomarkers, neuroimaging, and translational research—working toward earlier, more accurate diagnosis and better patient care.
Connecting careful clinical observation with modern biomarkers to solve difficult diagnostic problems in cognitive neurology.
Evaluating blood- and CSF-based biomarkers and understanding when biomarker results agree—or disagree—with established measures of Alzheimer disease pathology.
Improving recognition of rapidly progressive neurodegenerative syndromes and identifying clinical, imaging, and laboratory features that sharpen the differential diagnosis.
Studying diagnostic mimics and the real-world performance of tests used to distinguish prion disease from other causes of cognitive decline.
The Day-Lachner Lab brings together clinicians, researchers, trainees, and collaborators working across cognitive neurology, laboratory medicine, neuroimaging, and related disciplines.
Principal Investigator · Neurology
Investigator · Neurology
Full team profiles to be confirmed before launch.
Work presented on discordant plasma p-tau217, rapidly progressive dementia, and diagnostic utility of CSF 14-3-3 for prion disease.
Study examines clinical factors associated with discordant plasma p-tau217 and established Alzheimer disease biomarkers.
Interested in research at the intersection of cognition, biomarkers, and neurodegenerative disease? Opportunities and contact details will be added following institutional review.
Research inquiries →